Abstract
Nowadays, Mesenchymal stem cells (MSCs) have become one of the most attractive tools for treating tumors, due to their specific characteristics, the most prominent of which are tropism toward tumor. These cells will exert their effects through their secretion. In this study, our aim was to evaluate the anti-cancer effect of umbilical cord-derived mesenchymal cells (UCMSC) secretome, on MCF-7 tumor cells. MSCs were extracted from the umbilical cord of mothers, having normal delivery or cesarean section. After culture, the supernatants of these cells were collected and freeze-dried. The cytotoxic effect of freeze-dried secretome was examined at different concentrations on MCF-7 and the optimum concentrations (IC50) were calculated, using MTT assay. These results were confirmed by BrdU assay. The effect of induction of apoptosis of the MSC secretome on MCF-7 was determined, using annexin V/PI method by flow cytometry. The results of our study indicate that the isolation and growth time of UCMSCs of mothers who were naturally delivered was lower than those who received cesarean section. Co-culture studies showed that MSCs had cytotoxic effects on MCF-7 cells. The MSC secretome also showed cytotoxic effects on the MCF-7 cell line, this effect was mediated by induction of apoptosis, which was dose-dependent with an IC50 of 10 mg/mL.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allen H, Shraga-Heled N, Blumenfeld M, Dego-Ashto T, Fuchs-Telem D, Gilert A (2018) Human placental-derived adherent stromal cells co-induced with TNF-α and IFN-γ inhibit triple-negative breast cancer in nude mouse xenograft models. Sci Rep 8:670–687. https://doi.org/10.1038/s41598-017-18428-1
Bailey MM, Wang L, Bode CJ, Mitchel KE, Detamdre MS (2007) A comparison of human umbilical cord matrix stem cells and temporomandibular joint condylar chondrocytes for tissue engineering temporomandibular joint condylar cartilage. Tissue Eng 13:2003–2010. https://doi.org/10.1089/ten.2006.0150
Baksh D, Yao R, Tuan RS (2007) Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 25:1384–1392. https://doi.org/10.1634/stemcells.2006-0709
Chen X, Lin X, Zhao J, Shi W, Zhang H, Wang Y, Kan B, Du L, Wang B, Wei Y, Liu Y, Zhao X (2008) A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 16:749–756. https://doi.org/10.1038/mt.2008.3
Chen MY, Lie PC, Li ZL, Wei X (2009) Endothelial differentiation of wharton’s jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells. Stem Cell Bio 37:629–640. https://doi.org/10.1016/j.exphem.2009.02.003
Clarke MR, Imhoff FM, Baird SK (2015) Mesenchymal stem cells inhibit breast cancer cell migration and invasion through secretion of tissue inhibitor of metalloproteinase-1 and 2. Mol Carcinog 54:1214–1219. https://doi.org/10.1002/mc.22178
Du J, Zhou L, Chen X, Yan S, Ke M, Lu X (2012) IFN-γ-primed human bone marrow mesenchymal stem cells induce tumor cell apoptosis in vitro via tumor necrosis factor-related apoptosis-inducing ligand. Int J Biochem Cell Biol 44:1305–1314. https://doi.org/10.1016/j.biocel.2012.04.015
Dutta D, Heo I, Clevers H (2017) Disease modeling in stem cell-derived 3D organoid systems. Trends Mol Med 23:393–410. https://doi.org/10.1016/j.molmed.2017.02.007
Grisendi G, Bussolari R, Cafarelli L, Petak I, RasiniV VE, De Santis G, Spano C, Tagliazzucchi M, Barti-Juhasz H, Scarabelli L (2010) Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res 70:3718–3729. https://doi.org/10.1158/0008-5472
Hass R, Kasper C, Bohm S, Jacobs R (2011) Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. https://doi.org/10.1186/1478-811X-9-12
Hendijani F, Sadeghi-Aliabadi H, Haghjooy Javanmard S (2014) Comparison of human mesenchymal stem cells isolated by explant culture method from entire umbilical cord and Wharton’s jelly matrix. Cell Tissue Bank 15:555–565. https://doi.org/10.1007/s10561-014-9425-1
Hendijani F, HaghjooyJavanmard S, Sadeghi-Aliabadi H (2015) Human Wharton’s jelly mesenchymal stem cell secretome display antiproliferative effect on leukemia cell line and produce additive cytotoxic effect in combination with doxorubicin. Tissue Cell. https://doi.org/10.1016/j.tice.2015.01.005
Hernanda PY, Pedroza-Gonzalez A, Sprengers D, Peppelenbosch MP, Pan Q (2014) Multipotent mesenchymal stromal cells in liver cancer: implications for tumor biology and therapy. Biochim Biophys Acta 1846:439–445. https://doi.org/10.1016/j.bbcan.2014.08.008
Hong IS, Lee HY, Kang KS (2014) Mesenchymal stem cells and cancer: friends or enemies? Mutat Res 768:98–106. https://doi.org/10.1016/j.mrfmmm.2014.01.006
Houghton J, Morozov A, Smirnova I, Wang TC (2007) Stem cells and cancer. Semin Cancer Biol. https://doi.org/10.1016/j.semcancer.2006.04.003
Jin L, Zhang Y, Li H, Yao L, Fu D, Yao X, Xu LX, Hu X, Hu G (2012) Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis. Cell Res 22:1356–1373. https://doi.org/10.1038/cr.2012.90
Justus C, Leffler N, Ruiz-Echevarria M, Yang L (2014) In vitro cell migration and invasion assays. J Vis Exp 88:51046. https://doi.org/10.3791/51046
Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, Shi Y, Abbruzzese J, Konooleva M, Andereeff M, Marini F (2010) Mesenchymal stromal cells alone or expressing interferon-β suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 12:615–625. https://doi.org/10.3109/14653241003631815
Kim BC, Mamura M, Choi KS, Calabretta BS, Kim SJ (2002) Transforming growth factor β 1 induces apoptosis through cleavage of BAD in a Smad3-dependent mechanism in FaOhepatoma cells. Mol Cell Biol 22:1369–1378
Kudo-Saito C (2015) Cancer-associated mesenchymal stem cells aggravate tumor progression. Front Cell Dev Biol 3:23. https://doi.org/10.3389/fcell.2015.00023
Kusuma GD, Carthew J, Lim R, Feith JE (2017) Effect of microenvironment on mesenchymal stem cell paracrine signaling: opportunities to engineer the therapeutic effect. Stem Cells Dev 26:617–631. https://doi.org/10.1089/scd.2016.0349
Leng L, Wang Y, He N, Wang D, Zhao Q, Feng G (2014) Molecular imaging for assessment of mesenchymal stem cells mediated breast cancer therapy. Biomaterials 35:5162–5170. https://doi.org/10.1016/j.biomaterials.2014.03.014
Li M, Kh D, Ling-yee C, Si A, Par B (2018) Therapeutic delivery specifications identified through compartmental analysis of a mesenchymal stromal cell-immune reaction. Sci Rep. https://doi.org/10.1038/s41598-018-24971-2
Liang L, Yuebing W, He N, Di W, Qianjie Z, Guowei F, Weijun S, Yang X (2014) Molecular imaging for assessment of mesenchymal stem cells mediated breast cancer therapy. Biomaterials. https://doi.org/10.1016/j.biomaterials.2014.03.014
Lin HD, Fong CY, Biswas A, Choolani M, Bongso A (2014) Human Wharton’s jelly stem cells, its conditioned medium and cell-free lysate inhibit the growth of human lymphoma cells. Stem Cell Rev 10:573–586. https://doi.org/10.1007/s12015-014-9514-3
Liu X, Hu J, Sun S, Li F, Cao W, Wang Yu, Ma Z, Yu Z (2015) Mesenchymal stem cells expressing interleukin-18 suppress breast cancer cell in vitro. Exp Ther Med 9:1192–1200. https://doi.org/10.3892/etm.2015.2286
Lozito TP, Tuan RS (2011) Mesenchymal stem cells inhibit both endogenous and exogenous MMPs via secreted TIMPs. J Cell Physiol 226:385–396. https://doi.org/10.1002/jcp.22344
Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, Han ZB, Xu ZS, Lu YX, Liu D, Chen ZZ, Han ZC (2006) Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis—supportive function and other potentials. Haematologica 91:1017–1026
Luo X, Huang S, He N, Liu C, Chen Y, Liu Y, Mi X, Li N, Li Z, Xiang R, Su W (2018) Inflammatory human umbilical cord-derived mesenchymal stem cells promote stem cell-like characteristics of cancer cells in an IL-1β—dependent manner. BioMed. https://doi.org/10.1155/2018/7096707
Melzer C, von der Ohe J, Lehnert H, Ungefroren H, Hass R (2017) Cancer stem cell niche models and contribution by mesenchymal stroma/stem cells. Mol Cancer 16:28. https://doi.org/10.1186/s12943-017-0595-x
Norozi F, Ahmadzadeh A, Shahrabi S, Vosoughi T, Saki N (2016) Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells. Tumor Biol 37:11679–11689. https://doi.org/10.1007/s13277-016-5187-7
Pakravan K, Babashah S, Sadeghizadeh M, Mowla SJ, Mohammadi M, Ataei F, Dana N, Javan M (2017) MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1a/VEGF signaling axis in breast cancer cells. Cell Oncol 40:457–470. https://doi.org/10.1007/s13402-017-0335-7
Ren C, Kumar S, Chanda D, Chen J, Mountz JD, Ponnazhagan S (2008) Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 26:2332–2338. https://doi.org/10.1634/stemcells.2008-0084
Rhee KJ, Lee JI, Eom YW (2015) Mesenchymal stem cell-mediated effects of tumor support or suppression. Int J Mol Sci 16:30015–30033. https://doi.org/10.3390/ijms161226215
Sadri-Ardekani H, Mizrak SC, van Daalen SKM, Korver CM, Roepers-Gajadien HL, Koruji M, Hovingh S, Van Pelt A (2009) Propagation of human spermatogonial stem cells in vitro. JAMA 302:2127–2134. https://doi.org/10.1001/jama.2009.1689
Shah K (2012) Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deli Rev 64:739–748. https://doi.org/10.1016/j.addr.2011.06.010
Shreddy K, Troyer D, Weiss M (2008) Method to isolate mesenchymal-like cells from Wharton’s jelly of umbilical cord. Cell Biol 86:101–119. https://doi.org/10.1016/S0091-679X(08)00006-X
Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F (2008) Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 15:730–738. https://doi.org/10.1038/gt.2008.39
Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M (2002) Bone marrow-derived mesenchymal stem cells as vehicles for interferon beta delivery into tumors. Cancer Res 62:3603–3608
Tomasetti C, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B (2015) Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci 112:118–123. https://doi.org/10.1073/pnas.1421839112
Tomasetti C, Li L, Vogelstein B (2017) Stem cell divisions, somatic mutations, cancer etiology and cancer prevention. Science 355:1330–1334. https://doi.org/10.1126/science.aaf9011
Torsvik A, Bjerkvig R (2013) Mesenchymal stem cell signaling in cancer progression. Cancer Treat Rev 39:180–188. https://doi.org/10.1016/j.ctrv.2012.03.005
Tran C, Damaser MS (2015) Stem cells as drug delivery methods: application of stem cell secretome for regeneration. Adv Del Rev 82:1–11. https://doi.org/10.1038/s41598-018-23770-z
Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandz R (2017) Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci 18:1852. https://doi.org/10.3390/ijms18091852
Wagers AJ, Weissman IL (2004) Plasticity of adult stem cells. Cell 116:639–648. https://doi.org/10.1016/s0092-8674(04)00208-9
Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, Fu YS, Lai MC, Chen CC (2004) Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells 22:1330–1337. https://doi.org/10.1634/stemcells.2004-0013
Watson N, Divers R, Kedar R, Mehindru A, Mehindru A, Borlongan MC, Borlongan CV (2015) Discarded Wharton jelly of the human umbilical cord: a viable source for mesenchymal stromal cells. Cytotherapy 17:18–24. https://doi.org/10.1016/j.jcyt.2014.08.009
Xiuying LI, Jinping B, Xiaofeng JI, Ronggui LI, Yali X, Yimin W (2014) Comprehension characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation. Int J Mol Med 34:695–704. https://doi.org/10.3892/ijmm.2014.1821
Zhang Y, Liu S, Guo W, Wang M, Hao C, Gao S, Zhang X, Li X, Chen M, Jing X, Wang Z, Peng J, Lu S, Guo Q (2018) Human umbilical cord Wharton’s jelly mesenchymal stem cells combined with an acellular cartilage extracellular matrix scaffold improve cartilage repair compared with microfracture in a caprine model. Osteoarthr Cartil 26:954–965. https://doi.org/10.1016/j.joca.2018.01.019
Acknowledgements
This work has been supported by research council of Isfahan University of Medical Sciences, Project No. 394642. Authors express their special thanks to Dr. Mina Mirian for her valuable support in the cell culture lab during our experiments on cells.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Ethical approval
The umbilical cord samples were taken from infants of mothers who were delivered with the normal and/or cesarean section, after obtaining written consent from the parents and were in accordance with the ethical standards of the institutional research committee. This article does not contain any studies with animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mirabdollahi, M., Haghjooyjavanmard, S. & Sadeghi-aliabadi, H. An anticancer effect of umbilical cord-derived mesenchymal stem cell secretome on the breast cancer cell line. Cell Tissue Bank 20, 423–434 (2019). https://doi.org/10.1007/s10561-019-09781-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10561-019-09781-8